Association of tumor mutation burden and epidermal growth factor receptor inhibitor history with survival in patients with metastatic stage III/IV nonsmall-cell lung cancer: A retrospective study. Clinics [Internet]. 2021 Nov. 9 [cited 2024 Apr. 28];76:e2251. Available from: https://www.revistas.usp.br/clinics/article/view/192286